Table 1 Patient characteristics
No | Age (years) | Sex | Primary tumour | Tumour grade (Ki-67) | Prior therapies | Current therapies | Diagnosis to start PRRT (months) | Time between [18F]DOPA and [68Ga]DOTA-TOC (months) | Time between PRRT-end and death (months) | PRRT cycles | Cumulative activity administered by PRRT (GBq) | Time between last PET/CT and start PRRT (months) | Pre-CT to PRRTa (months) | PRRT to Post-CTb (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 55 | F | SI | G2 (2.8%) | Everolimus | Lanreotide | 11 | 5 | – | 4 | 30.1 | 5 | 0 | 2 |
2 | 70 | M | Colon | G2 (3.5%) | Surgery, interferon alpha, telotristat | Lanreotide, Octreotide SA | 37 | 13 | – | 4 | 29.9 | 9 | 2 | 2 |
3 | 58 | F | SI | G2 (10%) | Surgery | Octreotide SA | 39 | 1 | 5 | 2 | 14.9 | 5 | 2 | 2 |
4 | 74 | M | SI | G1 (< 2%) | Sandostatine | 97 | 1 | – | 4 | 30.1 | 5 | 5 | 11 | |
5 | 80 | M | SI | G2 (< 2%) | Surgery | Sandostatine | 181 | 1 | – | 4 | 29.6 | 2 | 3 | 2 |
6 | 67 | M | SI | G2 (< 2%) | Surgery | Lanreotide, Octreotide SA | 107 | 1 | – | 4 | 28.7 | 3 | 4 | 6 |
7 | 69 | F | Colon | G1 (< 2%) | Surgery, SSA | Sandostatine, | 38 | 1 | – | 4 | 29.1 | 2 | 3 | 4 |
8 | 70 | M | Lung | N/F (< 2%) | Octreotide SA | 36 | 5 | 27 | 4 | 29.7 | 3 | 3 | 2 |